MedPath

Plasma level of dabigatran comparison between geriatric and young patients with atrial fibrillatio

Phase 4
Conditions
Plasma level of dabigatran comparison between geriatric and young patients with atrial fibrillation
dabigatran, geriatric, atrial fibrillation, plasma level, therapeutic drug monitoring
Registration Number
TCTR20230208005
Lead Sponsor
Faculty of Pharmacy, Silpakorn University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending (Not yet recruiting)
Sex
All
Target Recruitment
90
Inclusion Criteria

1. Thai patient who was more than twenty years old and got dabigatran 150 milligrams or 110 milligrams twice daily for non-valvular atrial fibrillation indication.
2. Good compliance 100 percents and no change dabigatran at least 7 days.
3. The patient signed informed consent; if they can't decide, care given can sign informed consent.

Exclusion Criteria

1. Patient with mechanical valve replacement or moderate to severe mitral stenosis.
2. ESRD patient or creatinine clearance less than 30 ml/min.
3. Pregnancy or lactation patient.
4. Active bleeding
5. Platelet count less than 100,000 cell/mm3

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Dabigatran trough level 10-16 hours after the patient receives dabigatran Chromogenic assay,Dabigatran peak level 2-4 hours after the patient receives dabigatran Chromogenic assay
Secondary Outcome Measures
NameTimeMethod
/A N/A N/A
© Copyright 2025. All Rights Reserved by MedPath